In this study, we investigated antiepileptogenic and neuroprotective effects of the aqueous extract of roots (PDR) using and experimental models. In studies, status epilepticus caused by pilocarpine injection triggers epileptogenesis which evolves during about 1-2 weeks. After 2 h of status epilepticus, mice were treated during the epileptogenesis period for 7 days with sodium valproate and vitamin C (standards which demonstrated to alter epileptogenesis), or . The animals were then, 1 week after status epilepticus, challenged with acute pentylenetetrazole (PTZ) administration to test behaviorally the susceptibility to a convulsant agent of animals treated or not with the plan extract. Memory was assessed after PTZ administration in the elevated plus maze and T-maze paradigms at 24 and 48 h. Antioxidant and acetylcholinesterase activities were determined in the hippocampus after sacrifice, studies were conducted using embryonic rat primary cortical cultures exposed to L-glutamate. Cell survival rate was measured and apoptotic and necrotic cell death determined. The results showed that chronic oral administration of PDR significantly and dose-dependently increased the latency to myoclonic jerks, clonic seizures and generalized tonic-clonic seizures, and the seizure score. In addition, PDR at all doses (from 4.9 to 49 mg/kg) significantly decreased the initial and retention transfer latencies in the elevated plus maze. Interestingly PDR at the same doses significantly increased the time spent and the number of entries in T-maze novel arm. PDR significantly increased the activities of acetylcholinesterase and antioxidant enzymes superoxide dismutase, catalase, and total glutathione and proteins, and decreased malondialdehyde level. Furthermore, PDR increased viability rate of primary cortical neurons after L-glutamate-induced excitotoxicity, in a dose dependent manner. Altogether these results suggest that PDR has antiepileptogenic and neuroprotective effects, which could be mediated by antioxidant and antiapoptotic activities.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492699 | PMC |
http://dx.doi.org/10.3389/fphar.2017.00440 | DOI Listing |
Seizure
November 2024
Department of Clinical Neuroscience and Physiology, Salgrenska Academy, Goteborg University Goteborg, Blå Stråket 5, Sweden. Electronic address:
Drug discovery for the treatment of epilepsy is entering a new era especially with the advancement of genetic therapies as disease modifying, antiepileptogenic therapies. Even new ideas about re-purposed medication with purposed epileptogenic properties have been suggested. The possibilities are enormous, and it is encouraging that so many ideas are flourishing.
View Article and Find Full Text PDFFront Pharmacol
October 2024
Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health-New Orleans, New Orleans, LA, United States.
Background: Riluzole exhibits neuroprotective and therapeutic effects in several neurological disease models associated with excessive synaptic glutamate (Glu) release. We recently showed riluzole prevents acute excitotoxic hippocampal neural injury at 3 days in the kainic acid (KA) model of temporal lobe epilepsy (TLE). Currently, it is unknown if preventing acute neural injury and the neuroinflammatory response is sufficient to suppress epileptogenesis.
View Article and Find Full Text PDFCurr Mol Pharmacol
November 2024
Department of Physiology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.
Background: Status Epilepticus (SE) leads to the development of epilepsy with the contribution of Endoplasmic Reticulum (ER) stress. Uridine, a pyrimidine nucleoside, has been shown to have neuroprotective and antiepileptogenic effects in animal models. This study aimed to determine whether uridine ameliorates ER stress and apoptosis following epileptogenic insult.
View Article and Find Full Text PDFExp Neurol
December 2024
Department of Neurology and FM Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; PrevEp, Inc., Bethesda, MD, USA. Electronic address:
Post-traumatic epilepsy (PTE) is a recurrent and often drug-refractory seizure disorder caused by traumatic brain injury (TBI). No single drug treatment prevents PTE, but preventive drug combinations that may prophylax against PTE have not been studied. Based on a systematic evaluation of rationally chosen drug combinations in the intrahippocampal kainate (IHK) mouse model of acquired epilepsy, we identified two multi-targeted drug cocktails that exert strong antiepileptogenic effects.
View Article and Find Full Text PDFEpilepsy Curr
January 2024
Department of Pharmacology and Neuroscience, Creighton University School of Medicine, Omaha, NE, USA.
The integration of metabolic therapeutics in the available clinical armory is becoming more commonplace in health care as our understanding about the dependence of disease on metabolism continues to deepen and evolve. In the epilepsy field, we often think about the ketogenic diet (KD, high fat: carbohydrate ratio) in terms of its anti-seizure efficacy. The aim of this article is to review what we've learned from preclinical studies about the KD's more unconventional effects, including its neuroprotective effects, anti-epileptogenic and disease-modifying effects, and how the KD influences comorbidities associated with epilepsy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!